Why Athletes Take an Interest in Telmisartan
Telmisartan appears in gym conversations far more often than its licensed indications would suggest. It is a blood-pressure medicine, yet it is debated alongside supplements as a supposed metabolic aid and organ protector. Our editorial team sets out where that interest comes from, what the science supports and why the practice carries real risks in the UK context.
A blood-pressure drug with an unusual profile
Telmisartan is an angiotensin II receptor blocker licensed in the UK for hypertension and for reducing cardiovascular events in selected high-risk patients. It is taken once daily, has a long duration of action and is cleared through the liver rather than the kidneys.
What makes it stand out pharmacologically is partial activation of PPAR-γ, a nuclear receptor involved in fat cell differentiation, glucose handling and inflammation. Benson and colleagues identified this property in 2004, and it has been the engine of research interest ever since.
Other ARBs do not share this feature to the same degree, which is why telmisartan rather than losartan or candesartan dominates these discussions. The receptor activation at licensed doses is partial, however, and far weaker than that of a dedicated PPAR-γ agonist such as pioglitazone.
It is worth stating clearly at the outset: telmisartan is a prescription-only medicine. It is not a supplement, and it has no licensed role in enhancing performance or body composition.
Where the athletic interest comes from
Three strands feed the interest. The first is cardiovascular protection. Strength athletes, particularly those using anabolic agents or high-stimulant products, often develop raised blood pressure and left ventricular changes. An antihypertensive with evidence of organ protection is therefore attractive to them.
The second is metabolism. Animal studies have reported that telmisartan reduces fat accumulation, improves insulin sensitivity and increases markers of mitochondrial activity. Some rodent work has also described improvements in endurance capacity, attributed to PPAR-δ and PPAR-γ signalling in muscle.
The third is kidney and liver interest. Because ARBs reduce proteinuria and some small human studies have reported reductions in liver fat, telmisartan has acquired a reputation as a general-purpose protector of organs under strain.
These strands are not invented, but each is considerably weaker in humans than the online discussion implies, and none has produced a licensed indication beyond cardiovascular medicine.
What human evidence actually shows
The largest dataset comes from ONTARGET, in which more than 25,000 high-risk patients received telmisartan, ramipril or both. Telmisartan was comparable to ramipril for cardiovascular outcomes and better tolerated with respect to cough. The combination offered no benefit and caused more harm, including hypotension and renal events.
In metabolic terms, meta-analyses of randomised trials in hypertensive patients have reported small improvements in fasting glucose, insulin resistance indices and triglycerides with telmisartan compared with other ARBs. The effects are statistically detectable and clinically minor, and they were measured in patients with metabolic disturbance, not in lean trained individuals.
Studies in fatty liver disease, such as the comparison by Hirata and colleagues (2013), have suggested reductions in liver fat. These were small trials in patients who required antihypertensive treatment anyway. No regulator has approved telmisartan for liver disease.
Evidence of performance enhancement in humans is essentially absent. The endurance findings come from rodent models, and lowering blood pressure in someone who is normotensive is more likely to impair than improve exercise tolerance.
| Claim encountered online | Nature of the evidence | Reasonable interpretation |
|---|---|---|
| Improves insulin sensitivity | Randomised trials in hypertensive and metabolic-syndrome patients | Small real effect in those groups; unproven in healthy athletes |
| Reduces liver fat | Small clinical studies, animal work | Preliminary; not a licensed use |
| Protects the kidneys | Strong trial evidence in proteinuric kidney disease | Valid for patients with that diagnosis |
| Boosts endurance | Rodent studies only | No human support |
| Safe "organ support" for anyone | No evidence | Misleading; needs clinical indication |
Blood pressure in athletes deserves a proper diagnosis
Raised blood pressure in a trained person should be investigated, not self-treated. UK guidance (NICE NG136) recommends confirming a clinic reading with ambulatory or home monitoring, because single readings are unreliable and white-coat effects are common.
In athletes there are specific causes to consider. High-dose stimulants in pre-workout products, excessive caffeine, nicotine pouches, non-steroidal anti-inflammatories, sympathomimetic decongestants and anabolic-androgenic steroid use all raise blood pressure. Identifying and removing a cause is frequently more effective than adding a tablet.
Lifestyle factors matter as well: sodium intake, alcohol, sleep debt, bodyweight and sleep-disordered breathing, which is more common in heavily muscled individuals with large neck circumferences.
If medication is genuinely needed, the choice is a clinical decision. ARBs are often suitable, but the drug, dose and monitoring plan belong to a doctor who can also check interactions.
The practical problems with self-medication
Taking an antihypertensive without a diagnosis creates predictable problems:
- Hypotension: dizziness, light-headedness during heavy lifts or after hot training sessions, and risk of fainting.
- Hyperkalaemia: raised potassium, compounded by potassium supplements or potassium-sparing diuretics, with a risk of cardiac arrhythmia.
- Acute kidney injury: especially when combined with dehydration, NSAIDs or diuretic use.
- Masked pathology: treating a number while ignoring the cause, such as ongoing androgen or stimulant use.
- No pharmacist check: interactions with lithium, aliskiren, NSAIDs and potassium-affecting drugs go unnoticed.
Telmisartan is also absolutely contraindicated in pregnancy because of severe fetal harm, a point that is often missing from online discussions.
Buying prescription medicines from unregulated sellers brings the additional risk of counterfeit or mislabelled products. The MHRA's Yellow Card scheme exists for reporting suspected adverse reactions, and it depends on knowing what you actually took.
From an anti-doping perspective, telmisartan itself is not on the WADA Prohibited List, but that is not a safety endorsement, and athletes should always check the current list and declare medicines properly.
Conclusions of the editorial team
Telmisartan is a good antihypertensive with some genuinely interesting metabolic properties. Those properties are modest in humans, were measured in patients with cardiovascular or metabolic disease, and do not translate into a performance or physique benefit.
The athletic interest is best understood as a reasonable concern, protecting the heart and kidneys, channelled into an unreasonable solution, taking a prescription medicine without diagnosis or monitoring.
If your blood pressure is high, get it confirmed properly, look hard at stimulants and other substances, and let a clinician decide whether medication is warranted.
Readers may also wish to see our articles on home blood-pressure monitoring for lifters, on the cardiovascular effects of pre-workout stimulants, and on telmisartan's specific effects on the liver and kidneys.
References
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43(5):993–1002.
- Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229–235.
- National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline NG136. London: NICE; 2019.
- Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
- Hirata T, Tomita K, Kawai T, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease. Int J Endocrinol. 2013;2013:587140.
- https://anabolikusaruhaz.com/
